Skip to main content
Literatur
1.
Zurück zum Zitat Campbell EL, Bruyninckx WJ, Kelly CJ, Glover LE, McNamee EN, Bowers BE, et al. Transmigrating neutrophils shape the mucosal microenvironment through localized oxygen depletion to influence resolution of inflammation. Immunity. 2014;40(1):66–77.CrossRefPubMedPubMedCentral Campbell EL, Bruyninckx WJ, Kelly CJ, Glover LE, McNamee EN, Bowers BE, et al. Transmigrating neutrophils shape the mucosal microenvironment through localized oxygen depletion to influence resolution of inflammation. Immunity. 2014;40(1):66–77.CrossRefPubMedPubMedCentral
2.
Zurück zum Zitat Horvath R, Rozkova D, Lastovicka J, Polouckova A, Sedlacek P, Sediva A, et al. Expansion of T helper type 17 lymphocytes in patients with chronic granulomatous disease. Clinical and experimental immunology. 2011;166(1):26–33.CrossRefPubMedPubMedCentral Horvath R, Rozkova D, Lastovicka J, Polouckova A, Sedlacek P, Sediva A, et al. Expansion of T helper type 17 lymphocytes in patients with chronic granulomatous disease. Clinical and experimental immunology. 2011;166(1):26–33.CrossRefPubMedPubMedCentral
3.
Zurück zum Zitat Marciano BE, Rosenzweig SD, Kleiner DE, Anderson VL, Darnell DN, Anaya-O’Brien S, et al. Gastrointestinal involvement in chronic granulomatous disease. Pediatrics. 2004;114(2):462–8.CrossRefPubMed Marciano BE, Rosenzweig SD, Kleiner DE, Anderson VL, Darnell DN, Anaya-O’Brien S, et al. Gastrointestinal involvement in chronic granulomatous disease. Pediatrics. 2004;114(2):462–8.CrossRefPubMed
4.
Zurück zum Zitat Sandborn WJ, Gasink C, Gao L-L, Blank M, Johanns J, Guzzo C, et al. A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase2b Study of Ustekinumab, a Human Monoclonal Antibody to IL-12/23p40, in Patients With Moderately to Severely Active Crohn’s Disease: Results Through Week 22 From the Certifi Trial. Gastroenterology.140(5):S-109 Sandborn WJ, Gasink C, Gao L-L, Blank M, Johanns J, Guzzo C, et al. A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase2b Study of Ustekinumab, a Human Monoclonal Antibody to IL-12/23p40, in Patients With Moderately to Severely Active Crohn’s Disease: Results Through Week 22 From the Certifi Trial. Gastroenterology.140(5):S-109
5.
Zurück zum Zitat Song E, Jaishankar GB, Saleh H, Jithpratuck W, Sahni R, Krishnaswamy G. Chronic granulomatous disease: a review of the infectious and inflammatory complications. Clin Mol Allergy. 2011;9(1):10.CrossRefPubMedPubMedCentral Song E, Jaishankar GB, Saleh H, Jithpratuck W, Sahni R, Krishnaswamy G. Chronic granulomatous disease: a review of the infectious and inflammatory complications. Clin Mol Allergy. 2011;9(1):10.CrossRefPubMedPubMedCentral
6.
Zurück zum Zitat Rodrigues-Sousa T, Ladeirinha AF, Santiago AR, Carvalheiro H, Raposo B, Alarcao A, et al. Deficient production of reactive oxygen species leads to severe chronic DSS-induced colitis in Ncf1/p47phox-mutant mice. Plos One. 2014;9(5):e97532.CrossRefPubMedPubMedCentral Rodrigues-Sousa T, Ladeirinha AF, Santiago AR, Carvalheiro H, Raposo B, Alarcao A, et al. Deficient production of reactive oxygen species leads to severe chronic DSS-induced colitis in Ncf1/p47phox-mutant mice. Plos One. 2014;9(5):e97532.CrossRefPubMedPubMedCentral
7.
Zurück zum Zitat Kuijpers T, Lutter R. Inflammation and repeated infections in CGD: two sides of a coin. Cellular and molecular life sciences : CMLS. 2012;69(1):7–15.CrossRefPubMed Kuijpers T, Lutter R. Inflammation and repeated infections in CGD: two sides of a coin. Cellular and molecular life sciences : CMLS. 2012;69(1):7–15.CrossRefPubMed
8.
Zurück zum Zitat Rieber N, Hector A, Kuijpers T, Roos D, Hartl D. Current concepts of hyperinflammation in chronic granulomatous disease. Clinical & developmental immunology. 2012;2012:252460.CrossRef Rieber N, Hector A, Kuijpers T, Roos D, Hartl D. Current concepts of hyperinflammation in chronic granulomatous disease. Clinical & developmental immunology. 2012;2012:252460.CrossRef
9.
Zurück zum Zitat Uzel G, Orange JS, Poliak N, Marciano BE, Heller T, Holland SM. Complications of tumor necrosis factor-alpha blockade in chronic granulomatous disease-related colitis. Clin Infect Dis. 2010;51(12):1429–34.CrossRefPubMedPubMedCentral Uzel G, Orange JS, Poliak N, Marciano BE, Heller T, Holland SM. Complications of tumor necrosis factor-alpha blockade in chronic granulomatous disease-related colitis. Clin Infect Dis. 2010;51(12):1429–34.CrossRefPubMedPubMedCentral
10.
Zurück zum Zitat Sandborn WJ, Gasink C, Gao LL, Blank MA, Johanns J, Guzzo C, et al. Ustekinumab induction and maintenance therapy in refractory Crohn’s disease. The New England journal of medicine. 2012;367(16):1519–28.CrossRefPubMed Sandborn WJ, Gasink C, Gao LL, Blank MA, Johanns J, Guzzo C, et al. Ustekinumab induction and maintenance therapy in refractory Crohn’s disease. The New England journal of medicine. 2012;367(16):1519–28.CrossRefPubMed
Metadaten
Titel
Treatment of CGD-associated Colitis with the IL-23 Blocker Ustekinumab
verfasst von
Manish J. Butte
K. T. Park
David B. Lewis
Publikationsdatum
27.07.2016
Verlag
Springer US
Erschienen in
Journal of Clinical Immunology / Ausgabe 7/2016
Print ISSN: 0271-9142
Elektronische ISSN: 1573-2592
DOI
https://doi.org/10.1007/s10875-016-0318-x

Weitere Artikel der Ausgabe 7/2016

Journal of Clinical Immunology 7/2016 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.